Introducing bioZhena Core Technology (Ed.)

Introducing bioZhena Corporation’s core technology
Our Ovulona™ sensor is an unprecedented technology that detects the only 3 days in each
menstrual cycle during which – and only during which – pregnancy can result from
insemination, whether natural or artificial. The old commercially available fertility monitors
cannot do this.
We illustrate this with the following graphical comparison of the Ovulona 3-day fertile
window versus the fuzzy and much wider, uncertain, window indicated by the old
techniques.
3-day fertile window versus old methods' fuzzy
estimation of fertile period
0
5
10
15
20
-5 -4 -3 -2 -1 0 1 2
Days counted from ovulation
Numberofbirths
MEASUREOF
FERTILITY
Old Method
Ovulona
Because in the Old Methods ovulation was only guessed at, a fuzzy fertile period obtained.
Fuzzy and long. Wrong.
There is no device in the marketplace that could tell the user, in plain English, “today is
your first fertile day” - meaning that sex today is likely to lead to pregnancy. And from our
clinical trial results the user of the Ovulona will know that the pregnancy conceived on this
first of the fertile days is likely to be a male fetus, a boy.
There is no such fertility monitoring device that would subsequently confirm the pregnancy
within days – when, after detecting ovulation on the third day, the pregnant woman can no
longer register the usual follicular waves, and her Ovulona device interprets that change as
pregnancy detected, because that is how the biology works.
There is no device that would, in the event of pregnancy, calculate for the user the
scientifically predicted EDD, Estimated Delivery Date, so as to spare the woman of the
nerves, hassles and expenses associated nowadays with premature trips to the maternity
ward, and related hardships. Hardships suffered by expectant mothers because of the old
non-scientific way the doctors guesstimate and frequently mismanage the EDD today.
bioZhena Corporation
83 Davis Ranch Road, P.O. Box 122, Bellvue, Colorado 80512, USA
Vaclav Kirsner, Ph.D., Founder CEO
vaclavkirsner@yahoo.com
970-484-1272
Copyright Vaclav Kirsner, bioZhena Corporation Page 1 of 5

Again: There is no other device out there that would determine the only 3 days in each
menstrual cycle during which – and only during which – pregnancy can result from
insemination, whether natural or artificial. Neither can the other fertility monitors detect
delayed ovulation (which happens due to stress) or when ovulation does not occur at all.
Try for
a boy
Try for
a girl
Try for
either gender
The personal home-use device determines the 3 days during which conception can occur,
and it generates a new type of profile for use by the medical profession.
The folliculogenesis profile includes, among other things, the maturation of the dominant follicle before ovulation, and
follicular waves after ovulation.
There is no other comparable tool that would enable the patient and the healthcare system
to avoid the expense and hassle of trying to become pregnant with the help of the very
costly Artificial Reproductive Technologies at a time when the patient’s dominant follicle
maturation is not happening. This can only be achieved with our folliculogenesis-tracking
device for home use. The existing ovulation predictors cannot do this because tracking this
or that hormone does not determine the fertile window. Both the beginning and the end of
the fertile window require a proper orchestration of a multitude of hormonal and
neurological stimuli (not just an elevated E or LH, Estrogen or Luteinizing Hormone).
Ovulation must be detected, not just assumed from an LH peak as the urinalysis kits do.
970-484-1272

Absence of the peaksAbsence of the peaks
anticipates failure toanticipates failure to
ovulate.ovulate.
Ovulona anticipatesOvulona anticipates LPD =LPD =
Luteal Phase Defect, which oftenLuteal Phase Defect, which often
causes failure to conceivecauses failure to conceive –– byby
normal healthy womennormal healthy women
Ovulona’s
diagnostic power
will save infertility
treatment money.
This cannot be
matched by
ovulation kits or
by any other such
product.
The bioZhena venture involves an electronic device technology developed to make it
possible for every pregnancy to be deliberate, and to impact on women's healthcare and
public health in other ways, too. The existing products cannot do that.
Rationale: Much in women's health and lifestyle revolves around the menstrual cycle. We
monitor in vivo the process that causes the menstrual cycle phenomena. We monitor not
just one hormone or two, but the integrated effect of all neuroendocrine inputs on the
female reproductive system. We obtain the information from the part of the female body
that Mother Nature designed as the master monitor for reproductive management.
How do we do it? Picture a vaginal tampon applicator with a small electronic display. User
instructions advise use just like a tampon, but only for a few seconds, and for best results
970-484-1272

most every day. If the user skips, she receives a caution that reliability of her fertile window
determination is impaired, though still possible.
The user is in charge, and she decides whether the fertility status information is to help her
achieve pregnancy or to avoid becoming pregnant. We will supply statistical clinical trial
evidence for the efficacy of fertility status determination, this already FDA-certified for
aiding conception, and we will let the user decide what to do with the fertility status
information.
Our ovulographic™ technology is the definitive answer to the basic need of women
everywhere - natural and affordable reproductive management.
Our personal self-help fertility monitoring device, the Ovulona™, will tell the woman in plain
English (or Chinese, Italian, Arabic, etc.) whether today is one of the three days that she
can become pregnant. A three day window, unless stress causes delayed ovulation or
suppresses ovulation completely, either of which is then detected and allowed for, too.
(Only detectable by this technology.)
Further, since there is evidence for affecting the conceived baby’s gender by timing
conception with respect to ovulation, women can and will try to do that: Evidence suggests
that boys tend to be conceived on the first day of the fertile window versus girls on the day
of ovulation, which we detect separately from the multiple and repeatable anticipation of
ovulation. The important anticipation of ovulation is inherent in the sequence of the events
comprising the process behind menstrual cycling (folliculogenesis) – the cyclical
development of the ovum/egg that is viable only a few hours after ovulation.
Prospectively – as planned - with cervical cancer screening automatically going on in the
background; and with other uses (such as early pregnancy detection; data-based forecast
of the EDD, Estimated Date of Delivery; management of PMS/PMDD; management of
hormone therapy, to mention a few…).
The device generates and stores (and makes available to physicians) the data on a given
woman’s history of menstrual cyclic profiles, a new means of patient profiling - from post-
adolescence to peri-menopause.
Prospectively from being an aid for sex education in schools, through the family planning
years, all the way to peri-menopause management with individualized hormone therapy.
(We can also imagine trying this as a biofeedback tool for smoking cessation in women
because they find it very hard to quit once addicted, and this tool may help - since they will
see the bad effect smoking has on the cyclic profile and their reproductive health…)
This technology is not another ovulation kit or similar - it is not only for those who find it
difficult to become pregnant. We position the Ovulona to be a product that practically every
woman will want to use.
The woman of the 21st Century is envisaged to become accustomed to using her daily
Ovulona self-check about as routinely as she is using her toothbrush. This vision assumes
970-484-1272

that physicians will come to appreciate the advantage of having historical folliculogenesis
profiles of their patients correlated with symptom-registering data - based on which a better
diagnosis and better therapy can be provided to their patients.
We will offer to physicians a related data management appliance called the Ovulograph™,
based on our internal data processing tool for handling data from clinical trials.
Pre-ovulation rise of COPE scores
0
5
10
15
20
25
1
4
7
10
13
16
19
22
25
day of cycle
COPEscoresandprobe
readings[uA]
COPE score
probe reading/10
Post-ovulation rise of COPE scores
0
5
10
15
20
25
1
4
7
10
13
16
19
22
25
day of cycle
COPEscoresandprobe
readings[uA]
COPE score
probe reading/10
Ovulograph™
Physicians can correlate symptoms with folliculogenesis
COPE = Calendar of Premenstrual Experiences
In this example, the correlation enables differentiation between PMS/PMDD and clinical depression.
bioZhena Corporation seeks financing with which to manufacture the first batch of our first
marketable Ovulona products within 7 months, the first milestone towards envisaged
market dominance in scientific family planning™ (scientific fertility awareness™) and in
women’s health monitoring.
The prototype for use as a conceptive aid (as opposed to the birth control use and the
cervical cancer screen, etc.) has already been FDA-certified.
970-484-1272

Introducing bioZhena Core Technology (Ed.)

Recomendados

Recomendados

Más contenido relacionado

Destacado

Destacado (20)

Introducing bioZhena Core Technology (Ed.)